Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Wilkinson

Interventional Pain Medicine Johnson City, TN Medical Doctor

NPI 1679722052 CMS profile 638864

101 Med Tech Pkwy, Ste 200, Johnson City, TN 37604

Open in the dashboard

General payments

$34,526

612 records reported · program years 2019–2025

Research payments

$820

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Wilkinson of Johnson City, TN is reported in the CMS Open Payments database as having received $34,526 across 612 general payments and $820 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,482 67
2024 General $4,480 87
2023 General $2,953 112
2022 General $10,692 96
2021 General $10,313 82
2020 General $987 78
2020 Research $820 1
2019 General $1,620 90

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Wilkinson
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Michael Wilkinson were reported at $3,482. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Michael Wilkinson Interventional Pain Medicine median Middle half National median
2019 $1,620 $684 $216–$2,079 $163
2020 $987 $382 $122–$1,109 $114
2021 $10,313 $552 $167–$1,554 $132
2022 $10,692 $605 $187–$1,924 $149
2023 $2,953 $671 $195–$1,915 $160
2024 $4,480 $684 $206–$1,837 $164
2025 $3,482 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $29,102 370 payments
  2. Medtronic USA, Inc. $2,339 151 payments
  3. Nevro Corp. $997 24 payments
  4. Globus Medical, Inc. $542 8 payments
  5. Boston Scientific Corporation $324 9 payments
  6. SI-BONE, Inc. $177 3 payments
  7. Abbott Laboratories $171 11 payments
  8. Nalu Medical, Inc. $156 4 payments
  9. Vertos Medical, Inc. $147 1 payment
  10. Collegium Pharmaceutical, Inc. $113 9 payments
  11. Other $458 22 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $20,224 600 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $12,000 4 payments
  3. Travel and Lodging $2,302 8 payments
Products named General payments · program years 2019–2025
  1. INTELLIS ADAPTIVESTIM $13,317 270 payments
  2. INTELLIS Spinal Cord Neurostimulation $8,635 49 payments
  3. ADAPTIVESTIM $1,944 118 payments
  4. OSTEOCOOL RF ABLATION SYSTEM $1,566 11 payments
  5. Omnia $882 15 payments
  6. INCEPTIV $696 9 payments
  7. Accurian $659 14 payments
  8. Senza $318 9 payments
  9. WaveWriter Alpha Prime 16 $291 7 payments
  10. INTELLIS Spinal Cord Neurostimulation $281 16 payments
  11. Other $2,001 93 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic USA, Inc. $820 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

590

Median for Pain Management: 951

Drug cost

$8,333

Median for Pain Management: $26,034

Branded share of claims

34.4%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 95 $2,425
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 77 $2,126
Gabapentin Generic 68 $796
Oxycodone Hcl Generic 39 $595
Cephalexin Generic 98 $557
Tramadol Hcl Generic 42 $441
Ciprofloxacin Hcl Generic 65 $429
Methylprednisolone Generic 38 $425
Tizanidine Hcl Generic 21 $299
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 31 $146

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$130,305

Of which drugs: $1,172

Medicare patients

359

Average age 73

Services billed

2,588

233 women, 126 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 43%
Diabetes 35%
Ischemic heart disease 29%
Chronic kidney disease 27%
COPD 21%
Osteoporosis 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 15 1,060 $110

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Prialt
  • TerSera Therapeutics LLC $18
$18 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

613 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record